The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.
The Genomic Prostate Score (GPS) did not increase active surveillance acceptance compared with conventional risk counseling among patients with favorable-risk prostate cancer, according to data published in the Journal of Clinical Oncology.